No Data
No Data
Strong Buy Rating on Mind Medicine Backed by Positive Developments in MM120 Trials and Solid Financial Standing
Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD
Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18
Strong Financial Position and Promising Clinical Trials Underpin Buy Rating for Mind Medicine
Small Cap Stocks: Mind Medicine (MNMD) Is a Psychedelic Biotechnology Bet
Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript Summary
No Data
convivial Penguin_29 : but the patents tho...